Vimarsana
Biggest News Aggregation in the World

Macula Society News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Macula Society. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Macula Society Today - Breaking & Trending Today

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board - Vimarsana News

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

ZUG, Switzerland, May 30, 2024 -- Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members...

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant - Vimarsana News

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript - Vimarsana News

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments - Vimarsana News

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab , anti-TNF alpha eye drops in Dry Eye Disease ; topline results expected in Q2 2024Second Phase 3 trial of OCS-01 eye drops in Diabetic...

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor - Vimarsana News

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

Source: yahoo.com